Health Care · Services-Home Health Care Services

BTSG BrightSpring Health Services, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 186578256 filings
Russell 2000

BTSG at a glance

BrightSpring Health Services, Inc. (BTSG, SEC CIK 1865782) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as October 27, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), BrightSpring Health Services, Inc. (BTSG) reported revenue of $12.9 billion (up 14.6% from FY2024) and net income of $190.7 million. Diluted EPS was $0.87.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding BrightSpring Health Services, Inc. (BTSG) shares worth $5.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Greenwell Scott A. on September 14, 2026 of 15,099 shares at $57.91 per share.
  • In the last 90 days, BTSG insiders reported 0 open-market purchases ($0) and 1 open-market sale ($874K) on Form 4, a net sale of $874K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$12.9B
+14.6% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$874K
13F holders
32 funds
$5.0B · −2 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Integrated home and community-based healthcare platform delivering complementary pharmacy and provider services to complex Senior and Specialty patients
  • Strategic shift: Divestiture of Community Living business for $835M, focusing on streamlined Provider Services like home health, hospice, rehab, and primary care
  • New emphasis: Expanded home-based primary care and value-based care contracts leveraging integrated pharmacy-provider model to improve outcomes and reduce costs
  • Scale and reach: Serving over 465,000 patients daily via ~10,500 clinical providers and pharmacists across all 50 states, with 43M prescriptions filled in 2025
  • Noteworthy metric: Infusion and specialty pharmacy prescriptions grew 27%, home and community pharmacy 3% from 2024 to 2025, with 99.99% order accuracy and 99.34% completeness

Risk Factors

  • Medicare Home Health Prospective Payment System changes, including PDGM implemented 2020, affecting reimbursement based on patient mix and admission source
  • Exposure to Medicaid Integrity Program audits in six states, causing administrative costs and payment delays through 2029 under Review Choice Demonstration
  • Supplier relationship risk in Pharmacy Solutions, including loss of access to limited distribution pharmaceuticals impacting competitive positioning
  • Competition from vertically integrated rivals with exclusive pharmaceutical supply contracts and retail pharmacy chains limiting price competitiveness
  • Managed care contract risk with payors able to terminate contracts on 60-day notice, creating leverage to reduce volume or pricing favorable to payors

Management Discussion & Analysis

  • Consolidated revenue $12.91B in 2025, up 27.7% YoY from $10.12B in 2024; Pharmacy Solutions best performing segment, up 30.7% to $11.45B; Provider Services up 11.1% to $1.46B
  • Operating margin Pharmacy Solutions 3.8% vs 3.2%; Provider Services operating margin 14.0% vs 13.7%; consolidated EBITDA $776.2M, up 33.7% from $580.0M
  • Pharmacy Solutions segment EBITDA $543.5M, up 37.7%; Provider Services segment EBITDA $232.7M, up 13.3%; Pharmacy Solutions margin lower due to product mix shift
  • Net cash provided by operating activities $490.2M vs $23.8M; investing cash used $305.1M vs $140.2M (includes $144.8M acquisition spend); financing cash used $157.9M primarily debt repayment and $43.2M share repurchases
  • Management expects existing liquidity including $565.6M cash and revolving credit availability sufficient for next 12 months; key risks include integration costs, specialty drug mix shift affecting margins

AI summary of the BTSG 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Healthcare regulatory and compliance risk: 2025 10-K risk factors remain unchanged
  • Operational risk: Business disruption risks carried forward from the 2025 10-K
  • Financial risk: Financial-condition risks carried forward from the 2025 10-K
  • Unknown-risk exposure: Unidentified or currently immaterial risks could materially harm results

Management Discussion & Analysis

  • Revenue $4,213.2M, up $879.1M or 26.4% YoY
  • Gross margin 12.3% vs 11.8% YoY, operating margin 3.8% vs 2.6%
  • Best segment: Pharmacy Solutions revenue $3,732.4M, up 25.8%; EBITDA $202.0M, up 43.3%
  • Worst product line: Home and Community Pharmacy revenue $552.6M, down $37.4M or 6.3%
  • Cash $717.8M, operating cash flow $371.2M; $300.0M debt repayment and $120.0M share repurchases disclosed

AI summary of the BTSG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $4,213M, up 26.4%, with net income from continuing operations rising to $101M from $38M
  • Adjusted EBITDA $228M, up 42.0%, outpacing revenue growth and signaling operating leverage

Item 2.02: Results of Operations and Financial Condition

  • BrightSpring issued fiscal Q3 2026 results for the quarter ended September 30, 2026
  • Full financial details and management commentary available in Exhibit 99.1, the accompanying earnings release
Filed Jul 31, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $3,873M, up 23%, while Adjusted EBITDA $206M rose 44.2%; operating leverage strengthened materially
  • Net income from continuing operations $87M versus $9M, with diluted EPS $0.39 versus $0.04

Item 2.02: Results of Operations and Financial Condition

  • BrightSpring announced financial results for the quarter ended June 30, 2026
  • Results press release issued July 31, 2026
Filed Jun 12, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Dr. Nigam Shah appointed Class III director on June 11, 2026
  • Board’s Quality and Compliance Committee addition strengthens healthcare governance

Item 7.01: Regulation FD Disclosure

  • Dr. Shah appointed to BrightSpring Health Services’ Board
  • June 12, 2026 press release provides appointment details in Exhibit 99.1

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from 7 to 8 directors with Dr. Nigam H. Shah appointed as Class III director
  • Dr. Shah joins the Quality and Compliance Committee, strengthening board oversight of care and regulatory matters

AI summaries of BTSG 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BTSG

Don't miss the next BTSG filing

  • Alerts as it files. A push when BTSG files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BTSG, by share count.
  • Ask anything. An AI agent that reads every BTSG filing and answers with sources.

BTSG alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
ROUSSEAU JON BFOct 25, 2026$60.11
Greenwell Scott A.MSep 14, 2026$22.27
Greenwell Scott A.SellSep 14, 2026$57.91
Greenwell Scott A.MSep 14, 2026-
ROUSSEAU JON BFJul 25, 2026$72.91
Greenwell Scott A.FJun 20, 2026$66.25
KKR Phoenix Aggregator L.P.SellJun 5, 2026$58.45
Phipps Jennifer AMJun 5, 2026$6.37

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$11.3B$12.9B
Gross Profit-$1.6B$1.5B
Operating Income-$206.4M$295.3M
Net Income--$18.1M$190.7M
Gross Margin-14.1%11.8%
Op. Margin-1.8%2.3%
Net Margin--0.2%1.5%
Balance Sheet
Total Assets$5.5B$5.9B$6.4B
Equity-$1.6B$1.9B
ROE--1.1%10.2%
Per Share
EPS-$-0.09$0.87
Cash Flow
Operating CF-$23.8M$490.2M
CapEx$73.5M$80.9M$95.5M

Source: XBRL data in BrightSpring Health Services, Inc. (BTSG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BTSG share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BTSG shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$5.00B
Q2 202634$7.30B
Q1 202631$4.33B
Q4 202527$3.38B
Q3 202526$2.16B
Q2 202526$1.62B
Q1 202523$844.7M
Q4 202415$629.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 214 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BTSG filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KOct 30, 2026Analysis-
10-QOct 30, 2026Analysis
4Oct 27, 2026--
4Sep 16, 2026--
8-KJul 31, 2026Analysis-
SC 13GJul 31, 2026-
10-QJul 31, 2026Analysis
4Jul 28, 2026--
4Jun 22, 2026--
8-KJun 12, 2026Analysis-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
8-KJun 5, 2026Analysis
4Jun 5, 2026-
4Jun 5, 2026-
8-KMay 21, 2026Analysis
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
10-QMay 1, 2026Analysis
8-KMay 1, 2026Analysis-
4Apr 28, 2026--
8-KMar 31, 2026--
4Mar 31, 2026--

Related Health Care companies

All Health Care →

BTSG SEC filings: frequently asked questions

Are BTSG insiders buying or selling?

In the last 90 days, BrightSpring Health Services, Inc. (BTSG) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $874,383 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BTSG stock?

As of September 30, 2026, the largest BrightSpring Health Services, Inc. (BTSG) holders among the 13F filers tracked by SignalX were BlackRock ($1.2 billion), Invesco Ltd ($681.6 million), Vanguard Portfolio Management LLC ($504.5 million), T. Rowe Price Group ($473.3 million), Vanguard Capital Management LLC ($429.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BTSG's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), BrightSpring Health Services, Inc. (BTSG) reported revenue of $12.9 billion (up 14.6% from FY2024) and net income of $190.7 million. Diluted EPS was $0.87. The figures come from the XBRL data in the 10-K.

What are the main risks in BTSG's latest 10-K?

In the 10-K filed February 27, 2026, BrightSpring Health Services, Inc. (BTSG) flagged: Medicare Home Health Prospective Payment System changes, including PDGM implemented 2020, affecting reimbursement based on patient mix and admission source. Exposure to Medicaid Integrity Program audits in six states, causing administrative costs and payment delays through 2029 under Review Choice Demonstration. (AI summary of the Risk Factors section.)

What did BTSG report in its latest 8-K?

BrightSpring Health Services, Inc. (BTSG) filed an 8-K on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $4,213M, up 26.4%, with net income from continuing operations rising to $101M from $38M.

What are the latest BTSG SEC filings?

BrightSpring Health Services, Inc. (BTSG) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on October 27, 2026.

What is BTSG's SEC CIK number?

BrightSpring Health Services, Inc. (BTSG)'s SEC Central Index Key (CIK) is 1865782. EDGAR lists every BTSG filing under that number.

Ask anything about BTSG

The research agent reads BTSG's filings, financials, insider trades and 13F holders, then answers with sources.